Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

FDA Extends Capricor Deramiocel BLA Review — Aug 24, 2026Capricor Therapeutics announced that the FDA has extended the PDUFA target action date for its Deramiocel BLA for Duchenne muscular dystrophy from August 22, 2026 to November 22, 2026, following the submission of a BLA amendment with 24-month HOPE-3 open-label data and analyses supporting a refined indication focused on preserving upper limb function. The FDA classified the amendment as a major review and Capricor contends the extended data strengthen the case for addressing a significant unmet medical need in DMD, with HOPE-3 meeting its primary endpoint.